Detailed results from the FOURIER cardiovascular outcomes trial on evolocumab were presented at a late-breaking oral presentation at the American College of Cardiology meeting in Washington DC recently. This is the first major outcomes study to be published for a PCSK9 inhibitor – a new class of cholesterol-lowering medicines.
Never a week goes by without carbohydrates hitting the headlines, with heated debates raging over low carb diets for weight loss to sugar as “the new tobacco”. Sorting fact from fiction is hard for health professionals and patients alike. In this article we go behind the headlines to explore the truth about carbohydrates in a healthy diet.
The British Heart Foundation is pressing for a renewed focus on improving the diagnosis and management of familial hypercholesterolaemia, and adoption of a nationwide cascade screening programme for first-degree relatives. The article includes best practice tips for busy primary healthcare professionals.
This Back to Basics feature is a wallchart describing the functions of a healthy liver – the largest organ in the body. It carries out more than 500 tasks essential for life. This wallchart accompanies details on the new NICE guideline on non-alcoholic fatty liver disease.
A new study questions the feasibility and value of primary care screening for peripheral arterial disease (PAD). The PIPETTE study is the first UK study of PAD prevalence for nearly a decade.
Low socioeconomic status is linked to significant reductions in life expectancy and should be considered a major risk factor for ill health and early death in national and global health policies, according to a new study of 1.7 million people.
A new study shows that increased activity in the amygdala (the part of the brain involved in stress) is associated with a greater risk of heart disease and stroke. This study provides new insights into the possible mechanism by which stress can lead to cardiovascular disease in humans.
Offering smokers a taster session at an NHS Stop Smoking Service and explaining their personal risk of developing smoking-related diseases doubles their likelihood of attending a stop smoking course.
Liraglutide 1.2 mg has proved cost-effective when compared to alternative daily administered GLP-1 receptor agonists for the treatment of type 2 diabetes in the UK.